Gene therapy of cardiovascular disease

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 5, 2008, Pages 479-492

  Nikol, S ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Angiogenesis; Coronary artery disease; Gene therapy; Growth factor; Limb ischemia; Peripheral artery disease

Indexed keywords

ADENOVIRUS VECTOR; ALFERMINOGENE TADENOVEC; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOSOME; NATRIURETIC PEPTIDE TYPE C; PLACEBO; PLASMID DNA; PLASMID VECTOR; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN C;

ANGIOGENESIS; ANGIOPLASTY; ARTERY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MEGADOSE; DRUG SAFETY; FEVER; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; LIMB ISCHEMIA; LOW DRUG DOSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERIPHERAL EDEMA; RESTENOSIS; REVIEW; SIDE EFFECT; STABLE ANGINA PECTORIS; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC;

ANIMALIA;

EID: 53249119194     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science (1989) 244(4910):1342-1344.
2. Nabel EG, Plautz G, Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science (1990) 249(4974):1285-1288.
3. Leclerc G, Gal D, Takeshita S, Nikol S, Weir L, Isner JM: Percutaneous arterial gene transfer in a rabbit model. Efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest (1992) 90(3):936-944.
4. Heart disease and stroke statistics - 2008 update. American Heart Association, Dallas, TX, USA (2008). http://www.americanheart.org/presenter. jhtml?identifier=3000090
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J et al: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg (2007) 33(Suppl 1):S1-S75.
6. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg (2000) 31 (1 Pt 2):S1-S296.
7. Kim CB, Kesten R, Javier M, Hayase M, Walton AS, Billingham ME, Kernoff R, Oesterle SN: Percutaneous method of laser transmyocardial revascularization. Cathet Cardiovasc Diagn (1997) 40(2):223-228.
8. Horvath KA: Transmyocardial laser revascularization. J Card Surg (2008) 23(3):266-276.
9. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 333(26):1757-1763.
10. Klocke R, Kuhlmann MT, Scobioala S, Schäbitz WR, Nikol S. Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications. Curr Med Chem (2008) 15(10):968- 977.
11. Kuhlmann MT, Klocke R, Nikol S: Therapeutic angiogenesis for peripheral artery disease: Cytokine therapy. Vasa (2007) 36(4):253-260.
12. 165 in patient with ischaemic limb. Lancet (1996) 348(9024):370-374. •• This was the first cardiovascular gene therapy conducted in a patient.
13. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, Razvi S, Symes JF: Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results. J Vasc Surg (1998) 28(6):964-973.
14. Baumgartner I, Comerota AJ, Henry TD, Pasquet JP, Dedieu JF, Finiels F, Caron A, Bruder M, Ganster M, Delaere P: In vivo distribution and expression of FGF 1 transgene in patients with severe peripheral arterial occlusive disease (PAD). American Heart Association Scientific Sessions (2004):Abs 2438. • This study demonstrated for the first time the distribution and expression of a growth factor following intramuscular gene transfer in patients with PAD.
15. Ferrara N: Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol (1999) 237:1-30.
16. Helisch A, Schaper W: Angiogenesis and arteriogenesis - not yet for prescription. Z Kardiol (2000) 89(3):239-244.
17. Korpelainen EI, Alitalo K: Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol (1998) 10(2):159-164.
18. Cleaver O, Melton DA: Endothelial signaling during development. Nat Med (2003) 9(6):661-668.
19. Carmeliet P: Angiogenesis in health and disease. Nat Med (2003) 9(6):653-660.
20. Gibson CM, Ryan K, Sparano A, Moynihan JL, Rizzo M, Kelley M, Marble SJ, Laham R, Simons M, McClusky TR, Dodge JT Jr: Angiographic methods to assess human coronary angiogenesis. Am Heart J (1999) 137(1):169-179.
21. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, Simons M: Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol (1996) 270(5 Pt 2):H1791-H1802.
22. Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Caputo RP, Carrozza JP, Douglas PS, Sellke FW, Simons M: Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther (1997) 282(1):385-390.
23. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, Ferris B, Sanborn T, Isom P, Ferris B, Sanborn T et al: Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg (1998) 27(4):699-709.
24. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 93(2):662-670.
25. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W: Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res (2001) 49(3):543-553.
26. Schumacher B, Pecher P, von Specht BU, Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation (1998) 97(7):645-650.
27. 165 as sole therapy for myocardial ischemia. Circulation (1998) 98(25):2800-2804.
28. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M et al: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther (2008) 16(5):972-978. •• This phase II clinical trial demonstrated for the first time that angiogenic gene therapy can significantly reduce major amputation in patients with no option critical limb ischemia.
29. Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, Närvänen O et al: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation (2003) 107(21):2677-2683. •• This was the first phase II clinical trial of angiogenic gene transfer into the myocardium that compared adenoviral and nonviral gene transfer.
30. Gyöngyösi M, Khorsand A, Zamini S, Sperker W, Strehblow C, Kastrup J, Jorgensen E, Hesse B, Tägil K, Bøtker HE, Ruzyllo W et al: NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: Subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation (2005) 112(9 Suppl):I157-I165.
31. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L et al: Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol (2005) 45(7):982-988. •• This was the first phase II clinical trial of intramyocardial angiogenic gene transfer using the NOGA system.
32. Corautus Genetics: Corautus Genetics announces final efficacy results of GENASIS phase IIb clinical trial. Press Release (2006):October 11. http://www.medicalnewstoday.com/articles/53786.php
33. Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Ylä-Herttuala S: Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol Ther (2002) 6(1):127-133. •• This was the first completed phase II clinical angiogenic gene transfer trial in PAD.
34. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM, Sluiter WJ, Tio RA, Quax PH, Gans RO, Dullaart RP et al: Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther (2006) 17(6):683-691.
35. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 118(1):58-65.
36. Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N: Use of a constitutively active hypoxia-inducible factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase I dose-escalation experience. Circulation (2007) 115(10):1234-1243.
37. Rissanen TT, Vajanto I, Ylä-Herttuala S: Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic. Eur J Clin Invest (2001) 31(8): 651-666.
38. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation (2002) 105(11):1291-1297. •• The first completed phase II clinical trial of intramyocardial angiogenic gene transfer in patients with therapy-refractory angina.
39. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N: Angiogene Gene Therapy (AGENT-2) Study Group: A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol (2003) 42(8):1339-1347.
40. 121) versus maximum medical treatment. Gene Ther (2006) 13(21):1503-1511. •• The first phase II clinical trial of intramyocardial angiogenic gene transfer in patients using minithoracotomy.
41. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation (2003) 108(16):1933- 1938. •• The first completed phase II clinical angiogenic gene transfer trial in patients with intermittent claudication.
42. NCT00117650: Safety and efficacy study of Ad2/hypoxia inducible factor (HIF)-1α/VP16 gene transfer in patients with intermittent claudication (WALK). National Institutes of Health, Bethesda, MD, USA (2008). http://clinicaltrials.gov/ct2/show/NCT00117650?term=WALK&intr= hif-1&rank=1
43. Gene therapy clinical trials worldwide: John Wiley and Sons Ltd, Chichester, West Sussex, UK (2008). http://www.wiley.co.uk/genmed/clinical/
44. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ et al: Clinical trials in coronary angiogenesis: Issues, problems, consensus: An expert panel summary. Circulation (2000) 102(11):E73-E86.
45. Nikol S, Engelmann MG, Pelisek J, Fuchs A, Golda A, Shimizu M, Mekkaoui C, Rolland PH: Local perivascular application of low amounts of a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs. Acta Physiol Scand (2002) 176(2):151-159.
46. Laitinen M, Mäkinen K, Manninen H, Matsi P, Kossila M, Agrawal RS, Pakkanen T, Luoma JS, Viita H, Hartikainen J, Alhava E et al: Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther (1998) 9(10):1481-1486.
47. Rajagopalan S, Olin JW, Young S, Erikson M, Grossman PM, Mendelsohn FO, Regensteiner JG, Hiatt WR, Annex BH: Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther (2004) 15(6):619-624.
48. Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Ordén MR, Kholová I, de Goede A, Heikura T, Gröhn OH, Ylä-Herttuala S: Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation (2005) 112(25):3937-3946. • This study demonstrated the influence of blood flow on the type of new blood vessel formed.
49. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation (1998) 97(12):1114-1123.
50. Yla-Herttuala S, Alitalo K: Gene transfer as a tool to induce therapeutic vascular growth. Nat Med (2003) 9(6):694-701.
51. Hao X, Månsson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, Brodin LA, Sylvén C: Myocardial angiogenesis after plasmid or adenoviral VEGF-A165 gene transfer in rat myocardial infarction model. Cardiovasc Res (2007) 73(3):481-487. •• A systematic comparison of adenoviral and nonviral angiogenesis gene transfer.
52. Armeanu S, Pelisek J, Krausz E, Fuchs A, Groth D, Curth R, Keil O, Quilici J, Rolland PH, Reszka R, Nikol S: Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol Ther (2000) 1(4):366-375.
53. Pelisek J, Engelmann MG, Golda A, Fuchs A, Armeanu S, Shimizu M, Mekkaoui C, Rolland PH, Nikol S: Optimization of nonviral transfection: Variables influencing liposome-mediated gene transfer in proliferating vs. quiescent cells in culture and in vivo using a porcine restenosis model. J Mol Med (2002) 80(11):724-736.
54. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T et al: Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med (2006) 355(12):1222-1232.
55. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T et al: REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med (2006) 355(12):1210-1221.
56. Kawamoto A, Murayama T, Kusano K, Ii M, Tkebuchava T, Shintani S, Iwakura A, Johnson I, von Samson P, Hanley A, Gavin M et al: Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation (2004) 110(11):1398-1405. • This study demonstrated a synergistic interaction between gene and stem cell therapy.
57. Popma JJ, Ellis SG: Intracoronary stents: Clinical and angiographic results. Herz (1990) 15(5):307-318.
58. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ et al: A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med (2003) 348(16):1537-1545.
59. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest (1989) 83(5):1774-1777.
60. Popma JJ, Topol EJ: Factors influencing restenosis after coronary angioplasty. Am J Med (1990) 88(1N):16N-24N.
61. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 346(23):1773-1780.
62. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E et al: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation (2004) 109(2):190-195.
63. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R: Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol (2007) 27(7):1500-1510.
64. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW: Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 45(12):2088-2092.
65. Savage MP, Fischman DL, Schatz RA, Teirstein PS, Leon MB, Baim D, Ellis SG, Topol EJ, Hirshfeld JW, Cleman MW, Buchbinder M et al: Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. Palmaz-Schatz Stent Study Group. J Am Coll Cardiol (1994) 24(5):1207-1212.
66. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J et al: Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. J Am Med Assoc (2005) 294(10):1215-1223.
67. Erbel R, Haude M, Höpp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P: Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med (1998) 339(23):1672-1678.
68. Fuchs AT, Kuehnl A, Peslisek J, Rolland PH, Mekkaoui C, Netz H, Nikol S: Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty. Endothelium (2008) 15(1):93-100.
69. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G: Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation (2004) 110(7):810-814.
70. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U: Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 355(20):2113-2124.
71. Custodis F, Scheller B, Laufs U: Stable coronary artery disease - case report. Dtsch Med Wochenschr (2006) 131(11):554-555.
72. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation (2004) 109(6):701-705.
73. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 94(7):1690-1697.
74. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A: Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation (2002) 106(21):2649-2651.
75. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R: Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol (2006) 48(1):193-202.
76. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S et al: Coronary restenosis after sirolimus-eluting stent implantation: Morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 108(3):257-260.
77. Laitinen M, Hartikainen J, Hiltunen MO, Eränen J, Kiviniemi M, Närvänen O, Mäkinen K, Manninen H, Syvänne M, Martin JF, Laakso M et al: Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther (2000) 11(2):263-270.
78. Walter DH, Cejna M, Diaz-Sandoval L, Willis S, Kirkwood L, Stratford PW, Tietz AB, Kirchmair R, Silver M, Curry C, Wecker A et al: Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: An alternative strategy for inhibition of restenosis. Circulation (2004) 110(1):36-45. •• The first demonstration of gene-eluting stents for the inhibition of restenosis post-angioplasty.
79. 165 gene transfer prevents lumen loss through induction of positive arterial remodeling after PTCA in porcine coronary arteries. Atherosclerosis (2006) 189(1):123-132. • Prevention of restenosis post-angioplasty was shown using adventitial VEGF gene transfer.
80. Yla-Herttuala S: An update on angiogenic gene therapy: Vascular endothelial growth factor and other directions. Curr Opin Mol Ther (2006) 8(4):295-300.
81. Pelisek J, Kuehnl A, Rolland PH, Mekkaoui C, Fuchs A, Walker GF, Ogris M, Wagner E, Nikol S: Functional analysis of genomic DNA, cDNA, and nucleotide sequence of the mature C-type natriuretic peptide gene in vascular cells. Arterioscler Thromb Vasc Biol (2004) 24(9):1646-1651.
82. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet (1999) 354(9189):1493-1498.
83. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med (1998) 339(5):321-328.
84. Ohno N, Itoh H, Ikeda T, Ueyama K, Yamahara K, Doi K, Yamashita J, Inoue M, Masatsugu K, Sawada N, Fukunaga Y et al: Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation (2002) 105(14):1623-1626.
85. Morishige K, Shimokawa H, Yamawaki T, Miyata K, Eto Y, Kandabashi T, Yogo K, Higo T, Egashira K, Ueno H, Takeshita A: Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J Am Coll Cardiol (2000) 35(4):1040-1047.
86. Pelisek J, Fuchs AT, Kuehnl A, Tian W, Kuhlmann MT, Rolland PH, Mekkaoui C, Gaedtke L, Nikol S: C-type natriuretic peptide for reduction of restenosis: Gene transfer is superior over single peptide administration. J Gene Med (2006) 8(7):835-844. •• The first demonstration of long-term restenosis prevention via the dual effects of CNP local gene transfer in porcine femoral arteries.
87. Kühnl A, Pelisek J, Tian W, Kuhlmann M, Rolland PH, Mekkaoui C, Fuchs A, Nikol S: C-type natriuretic peptide inhibits constrictive remodeling without compromising re-endothelialization in balloon-dilated renal arteries. J Endovasc Ther (2005) 12(2):171-182. •• The first demonstration of long-term restenosis prevention via dual effects of CNP local gene transfer in porcine renal arteries.
88. Ng YS, D'Amore PA: Therapeutic angiogenesis for cardiovascular disease. Curr Control Trials Cardiovasc Med (2001) 2(6):278-285.
89. Cotton LM, O'Bryan MK, Hinton BT: Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction. Endocr Rev (2008) 29(2):193-216.
90. Valentis Inc: Valentis announces second quarter fiscal 2007 financial results. Press Release (2007): February 14.